Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (22504)	6/18/1998 11:35:00 PM
From: Machaon	Respond to of 32384

Henry, thanks for the response. << As I said earlier, many of the compounds slated to enter the clinic in the next 12-15 months were not even in the report of 19 months ago (which projected earnings out to 2006). I still think that the projects were conservative. >> Well, I have to admit that LGND's science is over my head. In fact, I'll bet that there is a bunch of us that are really investing in Henry Niman, via our investment in LGND. It would be interesting to know how many investors are holding LGND shares mainly because of your input. Calling $14 per share, by 2006, conservative, could be looked upon, by some, as hype. An EPS of $14, would translate into a LGND share price of around $420 (30 x EPS). 1000 shares, costing $12,750 now, would be worth $420,000 around 2005. Besides that, using "30 x EPS" could also be conservative, if LGND truly becomes that successful. While it certainly would be worth waiting for, it is an awful long time to live only on peanut butter (and tums for days like today). Regards, Bob